|
Palbociclib 125mg Clinical Trials
6 actively recruiting trials across 3 locations
No change since May 2026
Also known as: Ibrance, anti-CDK4/6
Pipeline
Phase 1: 2Phase 2: 2Phase 3: 1Phase 1/2: 1
Top Sponsors
- Weill Medical College of Cornell University1
- Relay Therapeutics, Inc.1
- Lebanese University1
- Forward Pharmaceuticals Co., Ltd.1
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Indications
- Cancer6
- Breast Cancer5
- Metastatic Breast Cancer3
- Rare Tumor1
- Locally Advanced Breast Cancer (LABC)1
Other3 trials
Chandler, Arizona1 trial
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Ironwood Cancer & Research Centers
Phase 3
Tucson, Arizona1 trial
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
The University of Arizona Cancer Center
Phase 1
New York, New York1 trial
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Weill Cornell Medicine
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.